Literature DB >> 23797667

Pulmonary expression of oncostatin M (OSM) promotes inducible BALT formation independently of IL-6, despite a role for IL-6 in OSM-driven pulmonary inflammation.

Fernando M Botelho1, Javier Rangel-Moreno, Dominik Fritz, Troy D Randall, Zhou Xing, Carl D Richards.   

Abstract

Inducible BALT (iBALT) is associated with immune responses to respiratory infections as well as with local pathology derived from chronic inflammatory lung diseases. In this study, we assessed the role of oncostatin M (OSM) in B cell activation and iBALT formation in mouse lungs. We found that C57BL/6 mice responded to an endotracheally administered adenovirus vector expressing mouse OSM, with marked iBALT formation, increased cytokine (IL-4, IL-5, IL-6, IL-10, TNF-α, and IL-12), and chemokine (CXCL13, CCL20, CCL21, eotaxin-2, KC, and MCP-1) production as well as inflammatory cell accumulation in the airways. B cells, T cells, and dendritic cells were also recruited to the lung, where many displayed an activated phenotype. Mice treated with control adenovirus vector (Addl70) were not affected. Interestingly, IL-6 was required for inflammatory responses in the airways and for the expression of most cytokines and chemokines. However, iBALT formation and lymphocyte recruitment to the lung tissue occurred independently of IL-6 and STAT6 as assessed in gene-deficient mice. Collectively, these results support the ability of OSM to induce B cell activation and iBALT formation independently of IL-6 and highlight a role for IL-6 downstream of OSM in the induction of pulmonary inflammation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23797667      PMCID: PMC4055037          DOI: 10.4049/jimmunol.1203318

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

1.  Aggregations of lymphoid cells in the airways of nonsmokers, smokers, and subjects with asthma.

Authors:  John G Elliot; Cathryn M Jensen; Slavko Mutavdzic; Jasmine P Lamb; Neil G Carroll; Alan L James
Journal:  Am J Respir Crit Care Med       Date:  2004-01-07       Impact factor: 21.405

2.  Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity.

Authors:  Juan E Moyron-Quiroz; Javier Rangel-Moreno; Kim Kusser; Louise Hartson; Frank Sprague; Stephen Goodrich; David L Woodland; Frances E Lund; Troy D Randall
Journal:  Nat Med       Date:  2004-08-15       Impact factor: 53.440

3.  Transgenic expression of granulocyte-macrophage colony-stimulating factor induces the differentiation and activation of a novel dendritic cell population in the lung.

Authors:  J Wang; D P Snider; B R Hewlett; N W Lukacs; J Gauldie; H Liang; Z Xing
Journal:  Blood       Date:  2000-04-01       Impact factor: 22.113

4.  Changes in the lymph node microenvironment induced by oncostatin M.

Authors:  Isabelle Louis; Gaël Dulude; Sophie Corneau; Sylvie Brochu; Catherine Boileau; Caroline Meunier; Caroline Côté; Nathalie Labrecque; Claude Perreault
Journal:  Blood       Date:  2003-04-17       Impact factor: 22.113

Review 5.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation.

Authors:  Peter C Heinrich; Iris Behrmann; Serge Haan; Heike M Hermanns; Gerhard Müller-Newen; Fred Schaper
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

Review 6.  The CC chemokine CCL20 and its receptor CCR6.

Authors:  Evemie Schutyser; Sofie Struyf; Jo Van Damme
Journal:  Cytokine Growth Factor Rev       Date:  2003-10       Impact factor: 7.638

7.  Oncostatin M regulates eotaxin expression in fibroblasts and eosinophilic inflammation in C57BL/6 mice.

Authors:  Carrie Langdon; Christine Kerr; Li Tong; Carl D Richards
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

8.  Sustained interleukin-6 signalling leads to the development of lymphoid organ-like structures in the lung.

Authors:  Sho Goya; Hiroto Matsuoka; Masahide Mori; Hiroshi Morishita; Hiroshi Kida; Yoichiro Kobashi; Terufumi Kato; Yoshio Taguchi; Tadashi Osaki; Isao Tachibana; Norihiro Nishimoto; Kazuyuki Yoshizaki; Ichiro Kawase; Seiji Hayashi
Journal:  J Pathol       Date:  2003-05       Impact factor: 7.996

Review 9.  Oncostatin M, a multifunctional cytokine.

Authors:  M Tanaka; A Miyajima
Journal:  Rev Physiol Biochem Pharmacol       Date:  2003-06-17       Impact factor: 5.545

10.  Oncostatin M, a cytokine released by activated mononuclear cells, induces epithelial cell-myofibroblast transdifferentiation via Jak/Stat pathway activation.

Authors:  Joanna Nightingale; Sharmila Patel; Naotaka Suzuki; Roger Buxton; Ken-ichro Takagi; Jun Suzuki; Yoshihiko Sumi; Atsushi Imaizumi; Roger M Mason; Zhi Zhang
Journal:  J Am Soc Nephrol       Date:  2004-01       Impact factor: 10.121

View more
  16 in total

1.  Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease.

Authors:  Kathryn L Pothoven; James E Norton; Kathryn E Hulse; Lydia A Suh; Roderick G Carter; Erin Rocci; Kathleen E Harris; Stephanie Shintani-Smith; David B Conley; Rakesh K Chandra; Mark C Liu; Atsushi Kato; Nirmala Gonsalves; Leslie C Grammer; Anju T Peters; Robert C Kern; Paul J Bryce; Bruce K Tan; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2015-04-01       Impact factor: 10.793

Review 2.  The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease.

Authors:  Kathryn L Pothoven; Robert P Schleimer
Journal:  Tissue Barriers       Date:  2017-06-13

3.  Oncostatin M reduces lesion size and promotes functional recovery and neurite outgrowth after spinal cord injury.

Authors:  Helena Slaets; Sofie Nelissen; Kris Janssens; Pia M Vidal; Evi Lemmens; Piet Stinissen; Sven Hendrix; Niels Hellings
Journal:  Mol Neurobiol       Date:  2014-07-05       Impact factor: 5.590

Review 4.  The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill.

Authors:  O Friedrich; M B Reid; G Van den Berghe; I Vanhorebeek; G Hermans; M M Rich; L Larsson
Journal:  Physiol Rev       Date:  2015-07       Impact factor: 37.312

5.  Oncostatin M overexpression induces matrix deposition, STAT3 activation, and SMAD1 Dysregulation in lungs of fibrosis-resistant BALB/c mice.

Authors:  Steven Wong; Fernando M Botelho; Rebecca M Rodrigues; Carl D Richards
Journal:  Lab Invest       Date:  2014-06-16       Impact factor: 5.662

Review 6.  Targetable pathogenic mechanisms in nasal polyposis.

Authors:  Alexander L Schneider; Robert P Schleimer; Bruce K Tan
Journal:  Int Forum Allergy Rhinol       Date:  2021-03-03       Impact factor: 5.426

Review 7.  The enigmatic cytokine oncostatin m and roles in disease.

Authors:  Carl D Richards
Journal:  ISRN Inflamm       Date:  2013-12-08

8.  Oncostatin M Induction of Monocyte Chemoattractant Protein 1 is Inhibited by Anti-oncostatin M Receptor Beta Monoclonal Antibody KPL-716.

Authors:  Carl D Richards; Rohan Gandhi; Fernando Botelho; Lilian Ho; John F Paolini
Journal:  Acta Derm Venereol       Date:  2020-07-02       Impact factor: 3.875

Review 9.  Inducible Bronchus-Associated Lymphoid Tissue: Taming Inflammation in the Lung.

Authors:  Ji Young Hwang; Troy D Randall; Aaron Silva-Sanchez
Journal:  Front Immunol       Date:  2016-06-30       Impact factor: 7.561

10.  Inflammation and autoimmunity in pulmonary hypertension: is there a role for endothelial adhesion molecules? (2017 Grover Conference Series).

Authors:  Wolfgang M Kuebler; Sébastien Bonnet; Arata Tabuchi
Journal:  Pulm Circ       Date:  2018-02-26       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.